10-K: Aytu BioPharma Reports FY2026 Results, Revenue Declines

Aytu BioPharma's fiscal year 2026 results show a net revenue decrease of 13.3% to $57.6 million, driven by declines in its ADHD and Pediatric portfolios, while launching its new MDD treatment, EXXUA.

Summary

• Aytu BioPharma reported a net revenue of $57.6 million for fiscal year 2026, a decrease of 13.3% from the prior year.
• The company experienced declines in its ADHD Portfolio ($45.8 million) and Pediatric Portfolio ($5.1 million), attributed to a strategic focus on the EXXUA launch.
• EXXUA, launched in fiscal year 2026, generated $6.6 million in net revenue.
• Operating expenses increased by $2.5 million in selling and marketing and $1.9 million in general and administrative costs, primarily due to EXXUA's commercialization efforts.
• The company reported a net loss of $14.3 million for fiscal year 2026, compared to a net loss of $13.6 million in fiscal year 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to declining revenues, increased operating expenses, and a net loss, despite the launch of a new product.

Positives

• Successful commercial launch of EXXUA in fiscal year 2026, generating $6.6 million in net revenue.
• Maintained production of ADHD medications (Adzenys and Cotempla) without supply chain interruptions.
• Net cash from operating activities turned positive at $3.3 million for fiscal year 2026, an improvement from negative $1.9 million in fiscal year 2025.
• Repaid the remaining $0.1 million outstanding balance of the Eclipse Incremental Advance in July 2026.
• Reclassified $26.4 million in derivative warrant liabilities to equity on March 31, 2026, due to warrant amendments.

Negatives

• Total net revenue decreased by 13.3% to $57.6 million in fiscal year 2026.
• ADHD Portfolio revenue decreased by 20.4% to $45.8 million.
• Pediatric Portfolio revenue decreased by 41.4% to $5.1 million.
• Gross profit percentage decreased to 64% from 69% in the prior year.
• Net loss increased to $14.3 million from $13.6 million in the prior year.

Risks

• Continued reliance on a limited number of significant customers, with five customers accounting for 83% of gross revenue in fiscal year 2026.
• Potential for generic competition, as evidenced by the patent infringement lawsuit against Granules Pharmaceuticals regarding Adzenys.
• The company may need to raise additional funding, which may not be available on acceptable terms.
• The terms of the loan agreement place restrictions on operating and financial flexibility.
• The company has incurred significant losses to date and can give no assurance of future profitability.

Future Outlook

The company expects selling and marketing expenses to increase in fiscal 2027 to support EXXUA's commercialization, driven by higher sales force costs and promotional activities. General and administrative expenses are also expected to rise in fiscal 2027 due to scaling commercial operations for EXXUA, including additional personnel and infrastructure investments. Research and development expenses are expected to remain minimal, primarily for regulatory filings and intellectual property maintenance.

Management Comments

• We believe focusing resources on our most profitable, growing products provides the most effective pathway to achieve company-wide profitability and continued growth.
• We believe EXXUA has the potential to serve as a major growth catalyst for us and we launched EXXUA in fiscal 2026 as a centerpiece of our commercial efforts.
• We are focusing our efforts on accelerating the growth of our commercial business and achieving positive operating cash flows.

Industry Context

StockSavvy.ai notes that Aytu BioPharma's focus on EXXUA aligns with the industry trend of seeking novel treatments for complex CNS diseases like Major Depressive Disorder, where significant unmet needs persist due to side effects of existing therapies.

Comparison to Industry Standards

• The MDD market in the US is valued at over $22 billion, with over 360 million antidepressant prescriptions written in 2025, indicating a large market for EXXUA.
• The ADHD medication market in the US generated $31.3 billion in sales in 2025, with stimulant medications accounting for approximately 88% of prescriptions.
• The prescription antihistamine market is a large category with approximately 56.4 million prescriptions written in 2025, dominated by generic products.

Legal Proceedings

• Patent infringement lawsuit filed against Granules Pharmaceuticals, Inc. regarding Adzenys, with trial scheduled for January 12, 2027.
• The Revive Investing lawsuit appeal is ongoing in the United States Court of Appeals for the Tenth Circuit.

Related Party Transactions

• In the first quarter of fiscal 2025, the company completed the divestiture of its Consumer Health business to a private company affiliated with former Vice President of Consumer Health, Jonathan Hughes.

Stakeholder Impact

• Shareholders may experience dilution from future equity financings.
• Lenders under the Eclipse Agreement may accelerate debt if covenants are breached.
• Customers (wholesalers and pharmacies) are concentrated, and loss of a major customer could impact revenue.
• Patients may benefit from the launch of EXXUA, a new treatment option for MDD with a potentially favorable side effect profile.

Next Steps

• Continue to accelerate adoption of EXXUA following its fiscal 2026 commercial launch.
• Continue to grow commercial branded, revenue-generating products by increasing sales and improving patient access.
• Leverage the Aytu RxConnect patient support platform to reduce access barriers.
• Lupin Pharma Canada Ltd is expected to seek local regulatory approvals and marketing authorizations for Adzenys and Cotempla in Canada over the next 12 months.
• The patent infringement lawsuit against Granules Pharmaceuticals regarding Adzenys is ongoing, with trial rescheduled to January 12, 2027.

Key Dates

Recommendation

While the launch of EXXUA is a positive step and the company is focusing on commercial growth, the overall decline in revenue, increased operating expenses, and continued net loss suggest a cautious approach. The company's ability to achieve profitability hinges on EXXUA's market adoption and managing its cost structure. The ongoing patent litigation and potential need for further capital also present risks.

Keywords

pharmaceutical, CNS diseases, EXXUA, MDD, ADHD, Adzenys, Cotempla, Karbinal